Bristol Myers Squibb (NYSE: BMY) has received accelerated FDA approval for Augtyro (repotrectinib), a treatment designed for patients 12 years and older with NTRK gene fusion-positive solid tumors. This approval, pivotal for patients with advanced stages of cancer where surgical options could cause severe morbidity, marks a significant advancement in targeted cancer therapy. Clinical Trial […]
AstraZeneca has finalized the acquisition of Fusion Pharmaceuticals Inc., a significant move valued at approximately $2.4 billion, designed to enhance its oncology portfolio by incorporating next-generation radioconjugates (RCs) for cancer treatment. This strategic acquisition not only expands AstraZeneca’s capabilities in targeted cancer therapy but also consolidates its research and development footprint in North America. Financial […]
FibroGen, Inc. (NASDAQ: FGEN) has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals, aiming to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron’s anti-PD-1 therapy, LIBTAYO (cemiplimab), in patients with solid tumors. This partnership marks a significant step in cancer research, potentially leading to more effective treatments for patients suffering […]
CStone Pharmaceuticals has reached a pivotal milestone in its global strategy, with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of sugemalimab, an innovative anti-PD-L1 monoclonal antibody, for the treatment of metastatic non-small cell lung cancer (NSCLC). This approval positions sugemalimab to be the first such […]
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have released promising new data from their collaborative study, ARC-9, during an oral session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase 1b/2 study assessed the efficacy of etrumadenant combined with zimberelimab, FOLFOX chemotherapy, and bevacizumab (EZFB) in treating […]
Eli Lilly and Company (Lilly, NYSE: LLY) has released updated data from its ongoing Phase 1/2 clinical trial for olomorasib, showcasing significant advancements in the treatment of advanced solid tumors with KRAS G12C mutations. The data, which highlights both monotherapy and combination therapy results with Merck’s KEYTRUDA (pembrolizumab), was presented at the prestigious 2024 American […]
AstraZeneca and Daiichi Sankyo have announced promising results from the TROPION-Lung01 Phase III trial, highlighting datopotamab deruxtecan’s potential as a treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). This trial marks a significant milestone as datopotamab deruxtecan, a TROP2-directed antibody drug conjugate (ADC), showed a clinically meaningful improvement in overall survival (OS) compared to […]
In a significant stride toward revolutionizing drug discovery and development, Seoul-based biotech firm Oncocross announced on May 22nd a renewed joint research agreement with JW Pharmaceutical. This collaboration aims to leverage artificial intelligence to accelerate the development of new drugs, particularly in the fields of anticancer and regenerative medicine. Leveraging AI for Faster, More Efficient […]
Novartis has announced a significant move in the oncology sector with its agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts. The transaction, valued at approximately $1.75 billion, including milestone payments, underscores Novartis’s commitment to advancing its capabilities in radioligand therapies (RLTs), a promising area of cancer treatment. Details of the […]
ANGLE plc, a leading innovator in liquid biopsy and circulating tumour cell (CTC) solutions, has announced a significant supplier agreement with global biopharmaceutical leader AstraZeneca PLC. The collaboration focuses on developing a novel methodology for the detection of micronuclei in CTCs, utilizing ANGLE’s DNA damage response (DDR) assay, a key marker in cancer diagnostics and […]